Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 3:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vaccine Administration Clear all
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 11, 2026, 3:24 PM EDT
Recruiting Phase 2 Interventional

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

NCT07806617
View directory record Official record
Conditions
Warts, Verruca (Warts), Verruca Vulgaris
Interventions
9-valent human papillomavirus vaccine, Sterile Saline
Biological · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1 Interventional

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

NCT01997190
View directory record Official record
Conditions
Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions
AdV-tk + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 11, 2026, 3:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
Biological · Drug
Lead sponsor
Nouscom SRL
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00828009
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, Tecemotide, carboplatin, cyclophosphamide, paclitaxel, radiotherapy
Biological · Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
88
States / cities
Palo Alto, California • Stanford, California • Macon, Georgia + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 11, 2026, 3:24 PM EDT
Suspended Phase 1 Interventional

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

NCT05378464
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab, T-Cell therapy
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Active, not recruiting Phase 1 Interventional

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NCT03361852
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Rituximab, Neo Vax, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Withdrawn Phase 2 Interventional

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

NCT03014804
View directory record Official record
Conditions
Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
Interventions
autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

NCT00124215
View directory record Official record
Conditions
Hepatitis C
Interventions
GI-5005
Biological
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 11, 2026, 3:24 PM EDT
Suspended Phase 1Phase 2 Interventional

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

NCT05101356
View directory record Official record
Conditions
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
Interventions
Antineoplastic Vaccine, Sargramostim, Pembrolizumab
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

NCT04142086
View directory record Official record
Conditions
Yellow Fever (Healthy Volunteers)
Interventions
Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine, Yellow fever vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 11, 2026, 3:24 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

NCT00971737
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 11, 2026, 3:24 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

NCT01031537
View directory record Official record
Conditions
Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
Interventions
FSME-IMMUN 0.5ml Baxter
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Hamilton, Montana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

NCT04639466
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Drug · Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Claremont, California • Duarte, California • Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Not listed Phase 1 Interventional

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

NCT04642937
View directory record Official record
Conditions
Glioblastoma
Interventions
Treatment with hP1A8
Drug
Lead sponsor
OX2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

NCT01738477
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 30 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
20
States / cities
Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 11, 2026, 3:24 PM EDT
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00022568
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant vaccinia-TRICOM vaccine
Biological
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1 Interventional

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

NCT01846143
View directory record Official record
Conditions
Melanoma
Interventions
pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

NCT04915768
View directory record Official record
Conditions
HIV Infections
Interventions
CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 11, 2026, 3:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 11, 2026, 3:24 PM EDT